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Abstract: The pandemic of overweight and obesity continues to rise in an alarming rate 
in western countries and around the globe representing a major public health challenge in 
  desperate need for new strategies tackling obesity. In the United States nearly two thirds of the 
population is overweight or obese. Worldwide the number of persons who are overweight or 
obese exceeded 1.6 billion. These rising figures have been clearly associated with increased 
morbidity and mortality. For example, in the Framingham study, the risk of death increases 
with each additional pound of weight gain even in the relatively younger population between 
30 and 42 years of age. Overweight and obesity are also associated with increased co-morbid 
conditions such as diabetes, hypertension and cardiovascular disease as well as certain types 
of cancer. In this review we discuss the epidemic of obesity, highlighting the pathophysiologic 
mechanisms of weight gain. We also provide an overview of the assessment of overweight and 
obese individuals discussing possible secondary causes of obesity. In a detailed section we discuss 
the currently approved therapeutic interventions for obesity highlighting their mechanisms of 
action and evidence of their efficacy and safety as provided in clinical trials. Finally, we discuss 
novel therapeutic interventions that are in various stages of development with a special section 
on the weight loss effects of anti-diabetic medications. These agents are particularly attractive 
options for our growing population of obese diabetic individuals.
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The recent decades have witnessed a rapidly growing pandemic of overweight and obe-
sity with an estimated of more than 1.6 billion of overweight or obese adults worldwide 
and at least 400 million among them being obese.1 The number of obese individuals is 
expected to continue to escalate in the coming years in both developed and developing 
countries. In the western world, and specifically in the United States, the prevalence of 
obesity has increased by 50% in each of the past two decades with two thirds of US 
population currently being overweight, nearly half of whom are obese.2 According to 
the National Health and Nutrition Examination Survey (NHANES) of 2003–2004, 
a nationally representative sample of the US population, 17.1% of US children and 
adolescents were overweight and 32.2% of adults were obese, with the major increase 
of prevalence occurring alarmingly among children, adolescents and men during the 
6-year period from 1999 to 2004.3 The NHANES data show that 71% of men and 
62% of women are overweight or obese, with prevalence varying among the major 
racial/ethnic groups in the US. Furthermore, the prevalence of clinically severe obesity 
is increasing much faster than obesity itself. For instance, between 1986 and 2000, 
the prevalence of a body mass index (BMI) of 40 or greater quadrupled from about Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 96
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1 in 200 adult Americans to 1 in 50, and the prevalence of a 
BMI of 50 or greater increased by a factor of 5, from about 
1 in 2000 to 1 in 400.4
Obesity has been historically associated with increased 
mortality and morbidity. The relationship between an 
increasing body weight and health risks is curvilinear with 
the BMI of 22 being associated with the lower risk. This 
link is clearly illustrated in the Framingham Heart Study that 
demonstrated increased risk of death by 1% for every pound 
of weight increase between the ages of 30 and 42 years and 
2% between the ages of 50 and 60 years.5 A more recent 
prospective study of a large National Institute of Health 
cohort suggested that the risk of death increased by 20% to 
40% among nonsmoker overweight persons and by at least 
2 to 3 times among obese persons.6
In addition to increased mortality, overweight and obesity 
have been associated with a wide spectrum of comorbidities 
including diabetes, hyperlipidemia, hypertension, cardiovas-
cular disease, arthritis, gout, gastro-esophageal reflux, chole-
lithiasis, obstructive sleep apnea, nonalcoholic steatohepatitis 
and certain types of malignancies such as cancer of breast, 
endometrium, ovaries, gallbladder, prostate and colorectum. 
In addition, obesity is at the core of the metabolic syndrome 
and insulin resistance predisposing patients to increased risk 
of cardiovascular disease and type 2 diabetes.
The burden imposed by the obesity pandemic is multifac-
eted making obesity a public health priority. In addition to the 
multiple health adverse effects, economic impact of obesity 
has been significantly striking.7 For example, it is estimated 
that the total direct cost of obesity-associated morbidity in 
the US was US$45.8 billion in 1990, representing 6.8% of 
all health care budget.8
Treating obesity should start by understanding the patho-
physiologic processes leading to weight gain. Obesity is a 
complex disease that involves multiple interactions between 
genetic and environmental factors. It has been estimated that 
30% to 40% of variance in BMI is due to genetic factors and 
60% to 70% is thought to be environmental.9 Furthermore, 
the genotype of obesity might have different phenotypic 
expression depending on environmental factors such as high 
fat diet and sedentary lifestyles. The epidemic of obesity is 
believed to be, at least partially, related to environmental 
changes, including increase in caloric intake and decrease 
in physical activity, with subsequent modulation of obesity 
gene expression.
During the initial evaluation of an obese patient, the 
physician should perform a comprehensive assessment in 
order to identify possible secondary causes of obesity as 
well as associated comorbidities that should be targeted 
in therapeutic plan. Goal setting, lifestyle changes and 
therapeutic options will be discussed in this paper with 
an emphasis on the role of pharmacotherapy in treating 
obesity.
Assessment of the obese patient
Assessment of an obese patient includes both clinical and 
laboratory evaluation to determine the degree of obesity, 
potential secondary causes and associated comorbidites in 
order to provide bases for selection of appropriate therapy.
Definition and severity of obesity
According to the World Health Organization and the US 
National Institute of Health, obesity is defined as a BMI 
over 30 kg/m2 and overweight as a BMI  25 kg/m2, with 
BMI being a standard clinical tool calculated by dividing a 
person’s weight in kilograms by height in meters squared.10 
Morbid obesity is defined by a BMI greater than 40 or a 
BMI greater than 35 with associated comorbidities (diabetes, 
hypertension, atherosclerosis). In pediatrics, overweight 
and obesity are defined by BMI  85th and 95th percentile 
respectively for age and sex for those aged 2 to 19 years.
BMI is an acceptable approximation of total body fat for 
most patients. However, those who are very muscular or have 
low muscle mass should have their total body fat determined 
from a monogram.
While BMI is the standard method of evaluating the 
overall degree of excess weight, measurement of waist 
circumference has emerged as a useful clinical tool in risk 
stratification of obese patients where increased central 
adiposity accounts for most of the increase of morbidity 
and mortality in this population.11 Excessive abdominal 
fat is associated with increased risk of diabetes mellitus, 
dyslipidemia, hypertension, cardiovascular disease, gall-
bladder disease, nonalcoholic fatty liver, sleep apnea, gout, 
osteoarthritis, and certain types of cancers, in addition to an 
overall increase in mortality A waist circumference greater 
than 40 inches (102 cm) in men and 35 inched (88 cm) in 
women is linked to higher cardiovascular risks and should 
lead to more aggressive weight reduction strategies in 
overweight patients.
Assessment of associated comorbidities
A major component of obesity management is the identifica-
tion and treatment of associated comorbidities, specifically 
cardiovascular risk factors. In all overweight or obese 
patients, a careful medical history including age of onset Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 97
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of obesity, smoking, family history, alcohol consumption, 
dietary habits, level of exercise and medications should be 
obtained. Blood pressure should be measured and labora-
tory testing should be obtained for screening of diabetes 
and hyperlipidemia.
Assessment of possible  
secondary obesity
In addition to baseline evaluation, initial assessment should 
be oriented to rule out rare but potentially treatable secondary 
causes of obesity.12
Most cases of obesity are usually attributed to overeating 
with or without lack of exercise, translating into an increased 
energy intake and decreased energy expenditure leading to 
excess weight. Nevertheless, obesity could be less commonly 
related to underlying endocrinologic or genetic disorder. 
The patient should be screened clinically and if needed by 
laboratory testing for hypothyroidism, Cushing disease, 
hypogonadism, polycystic ovaries syndrome, Growth 
  Hormone deficiency, hypothalamic disease and insulinoma. 
Such underlying diseases would require the initiation of 
appropriate and specific therapy.
On the other hand, the presence of hyperphagia and early 
severe obesity in a context of family history of early onset of 
obesity support a genetic disease such as leptin deficiency, 
whereas the presence of dysmorphic features with massive 
obesity in very young patients should suggest syndromic 
obesity such as Prader Willi Syndrome.
Certain medications can cause weight gain, including 
insulin, sulfonylureas, anti-epileptic drugs (carbamazepime, 
valproate), antipsychotic medications (clozapine, olanzap-
ine) and some antidepressants (amitryptilin, paroxetine). 
Alternative medications should be always considered in 
this case.
Finally smoking cessation is traditionally linked to weight 
gain that could be prevented with nicotine replacement and 
bupropion.
Therapeutic strategies for obesity
The main principle in obesity management is achieving a 
negative caloric balance with reduced caloric intake and 
increased caloric expenditure that will inevitably lead to 
weight loss and particularly fat mass reduction. While this 
approach seems to be simplistic, the clinical experience 
  indicates that only a minority of the population is able 
to apply and maintain negative caloric balance through 
decreased food intake and increased physical activity to the 
recommended 150 minutes per week.
Overview of the current guidelines
The alarming increase in overweight and obesity prevalence 
among the western population led to the development of 
several guidelines by national and international organiza-
tions, such as the National Heart, Lung, and Blood Institute 
(NHLBI), the American College of Physicians (ACP), 
and the United States Preventive Services Task Force 
(USPSTF).13–15 These guidelines are periodically updated 
to reflect the recent developments in the field of obesity 
management. Perhaps the most common theme among these 
guidelines is their ability to address the differential effect 
of obesity ie, total body fat versus abdominal obesity, as 
well as determining the absolute cardiovascular disease risk 
among the overweight and obese population. Based on this 
risk stratification, guidelines serve as tools for goal-setting 
behavioral and dietary therapy, lifestyle modification, as well 
as pharmacotherapeutic modalities. They also address other 
interventions as liposuction, bariatric surgery, highlighting 
risk/benefit ratio of these therapeutic options as a reflection 
of evolving data from clinical research in this area.
Setting goals for the obese patient
Setting goals for the obese patient prior to initiation of therapy 
is of crucial importance and helps identifying targets and 
motivations and avoiding frustrations and discontinuation 
of therapy. The main goal of treating an obese patient is to 
decrease his or her health risks of obesity-related metabolic 
disorders and cardiovascular disease, followed by psychological 
and secondary cosmetic benefits of weight reduction.
It has been clearly demonstrated that a modest weight 
reduction is sufficient to induce significant reduction of most 
comorbidities’ risks, as illustrated in the Diabetes Preven-
tion Program study where only 7% of body weight loss was 
associated with 58% reduction of progression to diabetes 
in individuals with impaired glucose tolerance.16 A modest 
weight loss (10% of body weight) achieved through life-
style changes is associated with significant improvement of 
  glycemic control, blood pressure control and cholesterol level 
in obese patients with diabetes, hypertension and hyperlip-
idemia.17,18 Prolonged caloric restriction appears to improve 
longevity in rodents through beneficial metabolic effects and 
potential anti-aging effect.19
Therefore target weight loss of 5% to 10% of body 
weight at 6 months, translated into approximatively one 
pound weight loss per week (0.45 kg), is the recommended 
initial target and represents a realistic goal for these patients. 
Long-term goal is maintenance of reduced weight and further 
weight reduction if desired.11Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 98
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Therapeutic plan for the obese patient
Behavioral changes represent the mainstay of treatment 
of obesity and are based on the combination of hypoca-
loric diet and increased physical activity. Patients with   
BMI  30 or patients with BMI  27 with one or more 
associated comorbidity who fail to achieve 5% of body 
weight loss after 6 months of therapeutic lifestyle changes 
should be offered pharmacotherapy as part of comprehen-
sive program for weight loss. Bariatric surgery is reserved 
for patients with resistant severe obesity including patients 
with BMI  40 or patients with BMI  35 with associated 
comorbidities. Adjunctive therapy with herbal medications 
is not recommended as it contains unpredictable amount of 
active ingredients that can be harmful and lack safety data 
for short or long-term use.10
Lifestyle changes in the 
management of obesity
The management of obesity is based on either decreasing 
energy intake or increasing energy expenditure to target a 
negative energy balance translating in net weight loss. As 
food is the single source of energy intake, reducing nutrient 
intake is the cornerstone in treating obesity. On the other 
hand, Energy Expenditure is divided into Basal Metabolic 
Rate (BMR), Energy Expended in Activity (EAA), and ther-
mic effect of food. EAA is the most variable component as 
it can account from 10% to 20% of total energy expenditure 
(in bedridden subjects) to 60% to 80% in athletes. Increas-
ing energy expended in activity can increase total energy 
expenditure 4- to 8-fold and thus enhances weight loss sig-
nificantly. Life therapeutic changes including hypocaloric 
diet and increased exercise are universally recommended as 
first line therapy in obese patients.
Dietary interventions
The core of dietary modifications in weight loss is to reduce 
caloric intake. The rate of weight loss is proportional to the 
negative energy balance between intake and expenditure. It 
is estimated that a decrease of 500 Kcal energy intake per 
day leads to one pound weight loss in one week (0.45 kg). 
Energy expenditure however varies with individuals and 
can be influenced by gender, age and genetics, male gender 
and younger age being associated with higher energy 
expenditure.
Hypocaloric diet
Low calories diet (LCD) is universally recommended for 
weight loss. It can achieve 8% of body weight loss and reduce 
abdominal fat content in 6 months, along with improvement 
in associated metabolic parameters.10
Eucaloric diets provide approximatively 22 to 25 Kcal/kg 
of body weight, equivalent to 2200 to 2500 Kcal in a person 
weighing 100 kg. As outlined earlier, in order to achieve a 
1 lb weight loss weekly, an intake deficit of 500 Kcal/day 
should be ensured. A low calorie diet usually provides 
1000 to 1500 Kcal/day, depending on the body weight and 
the weight loss rate desired. More severe caloric restriction 
could lead to more rapid weight loss at short term, but com-
parison of 400 versus 800 Kcal/day showed no difference 
in weight loss in the long term. Moreover very low caloric 
diets (800 Kcal) are associated with substantial nutritional 
deficiencies, lean mass loss, greater weight regain secondary 
to stable decrease in energy expenditure and increased risk 
of gallstones and cholecystitis due to increased peripheral 
mobilization of cholesterol.18
Alcohol, junk food, sweets and beverages are commonly 
avoided in LCD in view of their high energy stores and lack 
of other nutritional benefits. A balanced diet is recommended 
to prevent excessive protein breakdown during energy restric-
tion. Portions-controlled diet, where reduced caloric and 
nutritionally complete ready-to-use portions are provided 
in form of frozen meals and snack, has proven safety and 
efficacy in clinical trials.20
Low fat diet
Most obesity guidelines recommend decrease fat intake to 
less than 30% of total daily caloric intake, as high intake of 
saturated fats and trans fatty acids might be associated with 
obesity and increased cardiovascular risk.10 Although lower 
fat diets without caloric restriction help promote weight loss 
by reducing calorie intake, lower fat diets coupled with total 
calorie reduction produce greater weight loss than lower fat 
diets alone and are associated with beneficial cardiovascular 
effects.10
For example, the low calorie step I diet recommended 
by the National Cholesterol Educational Program (NCEP) 
advocates for a diet where Energy from total fat represent 
30% or less of caloric intake, with 8% to 10% of saturated 
fat, up to 15% of monounsaturated fat, and up to 10% of 
polyunsaturated fat and less than 300 mg of cholesterol per 
day. More than 55% of caloric intake is then provided by 
carbohydrates and no more than 15% by proteins. Advocates 
of low carbohydrate diet have blamed the increased intake 
of carbohydrates associated with low-fat diets in the esca-
lation of obesity and developed therefore concept of low 
  carbohydrate diet to achieve weight loss.21Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 99
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Low carbohydrate diet
Low-carbohydrate diet has recently become very popu-
lar for weight loss. It consists of decreased amount of 
  carbohydrate intake with no necessary restriction of energy 
intake. Atkins diet is a severely carbohydrate-restricted diet 
(20 g/day in the induction phase) that was described by 
Dr Atkins. The hypothesis behind this diet is that reducing 
insulin levels by reducing carbohydrate intake would lead 
to less hunger and fat deposit. Although it initially raised 
concern regarding a possible adverse effect on lipid metabo-
lism and ketosis, several clinical trials have established 
the safety and efficacy of low carbohydrate diet in weight 
reduction, along with favorable effects on lipids, glucose 
and blood pressure.21
Comparison of diets
Several trials have compared the efficacy and the metabolic 
effects of different popular diets.22,23 The consensus is that the 
best diet remains the one that the patient will best and longest 
adhere to. Therefore the diet choice should be individualized 
and the different options and goals should be discussed with 
each patient.
increased physical activity
Increased energy expenditure is a crucial component of any 
weight management program. In clinical trials, increased 
physical activity alone induced a slight weight loss 
(0.1 kg/week). Although exercise did not demonstrate any 
additive benefit in weight reduction when added to hypo-
caloric diet in some trials,24,25 moderate regular activity has 
consistently proven efficacy in weight loss maintenance and 
prevention of weight regain.26,27 Furthermore, it is believed 
that physical activity can help preventing loss of lean body 
mass in a hypocaloric diet, and may decrease abdominal 
fat even without associated weight loss.28 Beyond weight 
reduction effect, physical fitness improves insulin sensitivity 
along with glycemic, lipid and blood pressure control and is 
believed to reduce cardiovascular risk.10
Overweight or obese patient should be advised 30 to 
45 minutes of moderate intensity activity for 5 days weekly 
in adjunction to diet therapy.29 With this regimen, an addi-
tional 100 to 200 calories per day of energy can be expended. 
Calorie expenditure will vary depending on the individual’s 
body weight and intensity of activity.10 Individuals at risk 
should undergo exercise-stress testing before initiation of 
activity program. In order to reduce barriers of cost and to 
optimize adherence, home-based exercise program includ-
ing walking and using stairs, along with dividing activity 
in intermittent daily sessions, are effective strategies in 
implementing physical activity in the weight management 
program.30
Other nonpharmacologic  
therapy of obesity
Several trials have examined the effect of acupuncture on 
weight loss in obese subjects. Two recently published meta-
analyses have shown significant although moderate weight 
reduction (0.5–3 kg) with acumpuncture when compared with 
placebo, lifestyle changes or sibutramine.31,32 Interestingly, 
in a recent randomized controlled trial comparing auricular 
acupuncture with sham auricular acupuncture using placebo 
needles in 45 overweight or obese patients, no significant 
difference of weight reduction was achieved but changes 
in ghrelin and leptin levels were more favorable in the 
  intervention group.33
The limited duration, quantity and poor methodoligic 
quality of these trials weaken the evidence of efficacy of 
acupuncture in obesity and underline the need for larger 
randomized controlled studies to evaluate this safe and 
possibly effective weight reducing intervention.
Pharmacologic treatment of obesity
The National Heart, Lung and Blood Institute of the National 
Institutes of Health recommend to add pharmacologic therapy 
to treat overweight or obesity in patients with BMI  30 or 
patients with BMI  27 with obesity associated comorbid-
ity who had failed to lose weight after 6 months of lifestyle 
interventions.14
Despite the limited compliance and long-term efficacy 
of lifestyle changes along with the dramatic increase of 
prevalence of obesity and its associated health cost and 
comorbidities, very few medications have been developed 
to match the need for therapeutic agents targeting obesity. 
Only two medications (orlistat and sibutramine) are recently 
approved to be used, in conjunction with diet and exercise, 
for long-term therapy of overweight or obese patients. Older 
medications approved for short-term use of obesity more 
than 30 years ago lack data on efficacy and safety beyond 
6 months of treatment.
Based on their mechanism of action, weight-reducing 
agents can be mainly divided in two categories: medications 
that decrease energy intake through early satiety or appetite 
suppression (through increase of anorexigenic neurotrans-
mitters such as epinephrine, serotonin and dopamine) and 
absorption inhibitors (orlistat).Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 100
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Orlistat is the only absorption inhibitor available for treatment 
of obesity. In the USA, it was approved by the Food and Drug 
Administration (FDA) in 1999 for treatment of obesity and 
maintenance of weight loss, in conjunction with hypocaloric 
diet and exercise.
Orlistat is a nonsystemic hydrogenated derivative 
that reversibly binds to gastrointestinal lipase, interfer-
ing with the absorption of dietary fat by inhibiting the 
hydrolysis of fat into absorbable fatty acids and glycerol, 
leading to excessive fecal fat excretion. It is estimated 
that the absorption of up to 30% of dietary fat can be 
blocked by orlistat in a dose-dependent effect, therefore 
reducing total fat and caloric intake.34 In healthy subjects, 
the effect of orlistat on gastric lipase was very fast and 
potent (46.6%–91.4% of gastric lipase inhibition within 
minutes) whereas duodenal lipolysis reduction was more 
pronounced with the solid meal than liquid meals.35 Human 
pancreatic lipase inhibition was found to be high regard-
less of the meal. Overall, the effects of orlistat on fat 
excretion levels were found to be much greater with the 
solid (40.5%–57.4% of ingested fat) than with the liquid 
(4.2%–18.8%) test meals.35
The increased amount of fat reaching the colon can 
lead clinically to intestinal cramps, flatulence, diarrhea, 
fecal incontinence and oily spotting.36 Decreased oral 
fat intake minimizes the intestinal side-effects, promot-
ing a better adherence to low-fat diet and providing an 
additional potential mechanism of weight loss in these 
patients. It has been thought that such low-fat diet can 
be associated with increased carbohydrates intake, poten-
tially accounting for the slow weight regain observed on 
the second year of the treatment with orlistat.37 However 
an overall favorable glycemic effect has been observed 
in patients with impaired glucose tolerance treated with 
orlistat.38
Pharmacokinetics
Orlistat is minimally absorbed from the gastrointestinal tract. 
Systemically absorbed orlistat appears to be degrraded into 
two major metabolites. The major route of elimination is via 
the feces (primarily unabsorbed drug); less than 5% of a dose 
appears in the urine. A small degree of biliary excretion may 
occur. The local half-life of orlistat is 1 to 2 hours.
Efficacy in clinical trials
More than 29 randomized controlled studies evaluated the 
effect of orlistat on weight reduction and other metabolic 
parameters in different populations.39
At least 4 randomized, double-blinded placebo controlled 
trials of orlistat lasting two years have been published. 
Orlistat therapy was consistently associated with a modest 
weight loss, peaking at around 8 months of treatment, fol-
lowed by a progressive weight regain during the second year 
of treatment.38,40,41 For example, in one European multicenter 
study, 688 obese participants were assigned double-blind 
treatment with orlistat 120 mg (3 times a day) or placebo in 
conjunction with hypocaloric diet for the first year, and were 
reassigned double-blind treatment with orlistat or placebo 
with a weight maintenance (eucaloric) diet for the second 
year.40 In the first year, the group treated with orlistat lost 
significantly more weight than the placebo group (10.2% 
of initial body weight versus 6.1%, P  0.001). During 
the second year, patients who continued with orlistat had 
almost half of the weight regain observed in those switched 
to placebo (P  0.001), whereas patients switched from 
placebo to orlistat lost additional 0.9 kg during the second 
year of trial, compared with a mean weigh regain of 2.5 kg 
in patients who continued on placebo (P  0.001).40
The XENical in the prevention of diabetes in obese 
subjects (XENDOS) study provided data on 4 years orlistat 
treatment, which represents the longest duration of an obe-
sity medication trial.38 In a double-blind, prospective study, 
3305 obese patients were randomized to lifestyle changes 
plus either orlistat 120 mg 3 times a day or placebo. The 
maximal body weight decrease was achieved during the first 
year (11% of initial body weight) in the orlistat-treated 
group compared to 6% decrease in the placebo-treated 
group. Despite gradual regain during the remaining 3 years, 
mean weight loss after 4 years was significantly greater 
with orlistat when compared to placebo (5.8 vs 3.0 kg with 
placebo; P  0.001).
As shown by the above-mentioned studies, orlistat has 
also proven efficacy in weight loss maintenance. A multi-
center double-blind, placebo-controlled study demonstrated 
the superiority of orlistat at the dose of 120 mg 3 times a day, 
when compared to placebo, in preventing weight regain in 
729 subjects who succeeded to lose 8% of their initial body 
weight during a 6-months lead-in of a hypocaloric diet.42 
At 1 year, the placebo-treated patients regain 56% of their 
body weight, compared with 32.4% in the group treated with 
orlistat 120 mg 3 times a day.42Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 101
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In summary, orlistat is associated with 5%–10% body 
weight reduction and slower weight regain.43 In a metanalysis, 
Li reported an average of additional 2.89 kg of weight reduc-
tion (compared to placebo and diet), and a total of 8.13 kg 
weight loss at one year with orlistat therapy.39
Metabolic effects
In addition to its weight reducing properties, multiple studies 
demonstrated beneficial effects of orlistat on glucose and 
lipid metabolism.38,40,42,44–47
Orlistat therapy consistently demonstrates a favorable 
lipid effect beyond the effect of weight loss in overweight 
or obese patients with concomitant hypercholesterolemia.35 
The majority of clinical trials reported significant decrease 
of total cholesterol and LDL-cholesterol levels when 
compared to diet therapy alone. In a metanalysis, Hutton 
described a mean 6 months reduction of 0.43 mmol/L, 
0.34 mmol/L, 0.06 mmo/L and 0.08 mmol/L in total cho-
lesterol, low-density lipoprotein (LDL) cholesterol, high-
density lipoprotein (HDL) cholesterol and triglycerides 
respectively, fact that was observed in both low and high 
cardiovascular risk patients as well as diabetic patients.43
Moreover, orlistat therapy is associated with a favorable 
glycemic effect.
In the XENDOS study, orlistat treatment reduced the 
4 year cumulative incidence of diabetes by 37.3% when 
compared to placebo (9.0% vs 6.2%, P = 0.0032).38 Further 
subanalysis revealed that this diabetes prevention effect was 
mostly explained by a significant reduction of progression to 
diabetes in participants with impaired glucose tolerance test, 
who represented 21% of the study population.
Several clinical trials assessed the efficacy of orlistat 
strictly in diabetic patients.48,49 In Hutton’s metanalysis, one 
year of orlistat therapy was found to be significantly associ-
ated with a mean decrease of 0.4% of glycated hemoglobin 
A1C (HbA1C) and a mean decrease of 0.83 mmnol/L of fasting 
blood sugar , along with greater orlistat-induced reduction of 
dosage of antidiabetic medications such as insulin, metformin 
and/or sulfonylureas.43
Clinical trials in adolescents
In 2003, The FDA approved the use of orlistat for treating 
obesity in adolescents, based on the results of a multicenter, 
54-week, randomized, double-blind study of 539 obese adoles-
cents conducted in the US and Canada, where treatment with 
orlistat at a dose of 120 mg 3 times daily was safe and achieved 
greater weight reduction when compared to placebo.41 At the 
end of the study, BMI decreased by 0.55 with orlistat but 
increased by 0.31 with placebo (P = 0.001).41
Safety and tolerability
Orlistat has generally been considered a safe medication 
as it is mostly not absorbed. However it can interfere with 
the absorption of fat-soluble vitamins such as vitamins D, 
A, K, E and beta-carotene. Levels of these vitamins, espe-
cially vitamin D levels, were observed to be lowered during 
therapy.36 There was no report of increased risk of gallstones 
or kidney stones with orlistat.36
Except for cyclosporine which should be given two hours 
before or after orlistat, there is no major drug interactions 
described with orlistat.36
As mentioned earlier, orlistat has side effects related to 
fecal fat loss that include soft or liquid stools, oily stools, 
fecal incontinence, abdominal pain, oily spotting, nausea 
and vomiting. These gastrointestinal side effects affected 
15% to 30% of patients across different clinical trials and 
usually subsided in 15% to 30% of patients after a few weeks 
of treatment.36 A randomized controlled study of sixty obese 
women receiving orlistat with psyllium mucilloid or orlistat 
with placebo suggested that the addition of natural fibers can 
ameliorate the gastrointestinal side-effects of orlistat without 
decreasing its efficacy.50
In August 2009, the FDA posted an early communication 
about an ongoing safety review regarding reports of liver-
related adverse events in patients taking orlistat.51 Between 
1999 and October 2008, 32 reports of serious liver injury, 
27 of which required hospitalizations, including 6 cases of 
liver failure, were reported to the FDA’s Adverse Events 
Reporting System. Thirty of the 32 reports occurred outside 
the US. The most common reported adverse effects were 
jaundice, weakness and abdominal pain. FDA analysis of the 
data is still ongoing and no definite association between liver 
injury and orlistat has been established at this time.51
Orlistat therapy is contraindicated in patients with 
  malabsorption or cholestasis and should be used with caution 
in patients with history of calcium oxalate nephrolithiasis or 
at who are at high risk of fat-soluble vitamin D deficiency.
Availability, dosage and administration
Orlistat is approved for marketing in approximately 
100 countries. In the US, it is two products aremarketed: 
  Xenical® (orlistat 120 mg) was approved as a prescrip-
tion product by FDA in 1999 for obesity management in 
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reduction maintenance. In 2007, Alli® (orlistat 60 mg) was 
approved for OTC use for weight loss in overweight adults, 
18 years and older, in conjunction with a reduced-calorie and 
low-fat diet. In January 2009, a nonprescription version of 
orlistat was approved for sale in the European Union.
Orlistat is usually administered at the dose of 60 or 
120 mg by mouth 3 times a day before or up to 1 hour 
after fat-containing meals. Treatment with orlistat should 
be associated with balanced and hypocaloric diet where 
approximately 30% of caloric intake is from fat. Although 
vitamin deficiency was not observed to be clinically relevant 
in the studies, it is recommended to supplement patients with 




Sibutramine is the only sympathomimetic drug approved 
for long-term treatment of obesity in Europe and the US. 
It was approved by the FDA in 1997 for long-term therapy 
of obese patients with or without diabetes, hyperlipidemia 
and/or stable hypertension.
Sibutramine acts, at the nerve uptake, through the mixed 
selective inhibition of reuptake of norepinephrine and sero-
tonin (5-hydroxytryptamine, 5-HT), and to a lesser degree 
dopamine, by centrally decreasing appetite. The drug and its 
metabolites bind weakly to serotonin (5-HT(1), 5-HT(1A), 
5-HT(1B), 5-HT(2A) and 5-HT(2C)), dopamine (D(1) 
and D(2)), norepinephrine (beta, beta(1), beta(3), alpha(1) 
and alpha(2)), benzodiazepine and glutamate (N-methyl- 
D-aspartate (NMDA)) receptors. It does not possess any anti-
cholinergic or antihistaminergic activity and it does not stimu-
late the release of serotonin, norepinephrine or dopamine.
In clinical trials, short-term as well as long-term sibtra-
mine treatment was associated with decreased appetite and 
respectively an average of 16% and 27% reduction in the 
amount of food intake.52
In addition to appetite suppression, a thermogenic effect 
was also observed in animal models but has been controver-
sial in humans.53
Pharmacokinetics
Sibutramine is rapidly absorbed after oral administration 
and reaches its peak plasma concentration within 1 to   
2 hours after administration. The drug and its active metabo-
lites (monodesmethyl M1 and didesmethyl M2) are mostly 
bound to proteins and undergo hepatic metabolism by 
cytochrome P450 enzymatic system (isoenzyme CYP3A4), 
causing eventual interference with many drugs, specifically 
eryhtromycine and ketokonazole. The majority of excre-
tion is renal with a half life of active metabolites of 14 to 
16 hours.
Clinical trials
Several randomized controlled trials evaluating sibutramine 
and lasting for 6 to 24 months have been published.26,54–58
In a multicenter dose-ranging study, 1047 obese subjects 
were assigned to treatment with 1 of 6 doses of sibutra-
mine (1, 5, 10, 15, 20, or 30 mg) or placebo once daily for 
24 weeks.57 A significant dose-related weight reduction, rang-
ing from 3.9% to 9.4% of body weight, was demonstrated 
across all time-points for a 5 mg/day to 30 mg/day dosage 
of sibutramine compared to placebo. Weight regain was 
observed after discontinuation of the medication.
Sibutramine efficacy in weight loss maintenance has been 
evaluated in three randomized controlled studies.26,56,58 In a 
European milticenter trial, The Sibutramine trial in Obesity 
Reduction and Maintenance, 605 obese patients were treated 
for 6 months with sibutramine 10 mg daily and hypocaloric 
diet.58 The 467 subjects who achieved more than 5% weight 
loss were then randomly assigned to 10 mg/day sibutramine 
or placebo for a further 18-month period. Only 16% of the 
placebo group subjects maintained 80% or more of their 
original weight loss at 2 years, compared with 43% in the 
sibutramine group. Similar findings were observed with the 
other maintenance trials.
The possibility of intermittent treatment with sibutra-
mine was examined in a German randomized, double-blind, 
  parallel-group placebo-controlled trial. In this 48-week trial, 
1001 obese subjects were randomly assigned to receive 
sibutramine 15 mg daily continuously, sibutramine 15 mg 
daily intermittently during weeks 1–12, 19–30, and 37–48, 
with placebo during the other weeks or just placebo after 
the run in period. Mean additional weight loss achieved at 
44 weeks was 3.8 kg (4.0%) and 3.3 kg (3.5%) in patients 
receiving continuous and intermittent therapy respectively, 
versus a mean weight gain of 0.2 kg (0.2%) in patients receiv-
ing placebo, demonstrating a therapeutic equivalence and a 
similar safety profile of the two sibutramine regimens.
Of note, one behavioral study demonstrated that the 
combination of sibutramine and lifestyle changes was sig-
nificantly at least twice more effective than either therapy 
alone, underlying the importance of conjunction of lifestyle 
counseling with pharmacotherapy.59
In summary, clinical trials demonstrated the efficacy of 
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loss induction and maintenance. Among several published 
meta-analysis, Li et al estimated the mean difference of 
weight loss with sibutramine to be 4.45 kg when compared 
to placebo in 5 long-term studies (44–54 weeks).39
Metabolic and cardiovascular effects
Favorable metabolic effects have been consistently observed 
with sibutramine across several clinical studies.
Several double-blinded controlled trials and meta-analysis 
have assessed the effect of sibutramine in diabetic patients.60–62 
In addition to a mean difference of weight loss of 4.63 kg 
when compared to placebo, sibutramine was associated with 
decreased waist circumference along with slight decrease in 
HbA1C and fasting blood glucose levels in obese patients with 
diabetes.61 These changes correlated with the magnitude of 
weight loss achieved.
Favorable lipid effects were also reported in diabetic and 
nondiabetes patients with specifically lower triglycerides and 
higher HDL cholesterol in sibutramine treated patients when 
compared to placebo-treated subjects. Nonetheless, this effect 
was not consistent in Li et al meta-analysis.39
Sibutramine use was commonly associated with a slight 
increase in diastolic and systolic blood pressure (1–3 mmHg) 
and slight increase in heart rate (4 beats per minute).39,63 This 
increase is probably linked to norepinephrin effect of sibutra-
mine. Beta-blockers do not appear to prevent this effect.64 
In a subgroup analysis, the effect on systolic blood pressure 
was greater with higher doses (15 mg daily), in younger 
patients (44 years of age) and individuals weighing above 
92 kg.65 Few randomized controlled study of sibutramine use 
in hypertensive patients have been published and revealed 
slight increase in diastolic blood pressure and heart rate.64,66–68 
Interestingly, in a recent study of hypertensive obese patients 
on different antihypertensive combined regimens, Scholze 
et al demonstrated that angiotensin-converting enzyme inhibi-
tors and calcium channel blockers are more advantageous 
than a beta-blocker/diuretic-based regimen in supporting the 
weight-reducing actions and concomitant metabolic changes 
induced by sibutramine in obese hypertensive patients.68
Clinical trials in adolescents
Sibutramine was also evaluated in the treatment of obesity 
in adolescents. 69,70 In a US multicenter randomized double-
blind trial, 498 obese adolescents received site-specific 
behavior therapy plus sibutramine daily or placebo. At 
12 months, the sibutramine group had greater reduction in 
BMI (−2.9 kg/m2) and body weight (−8.4 kg) than placebo 
group, with favorable lipid and glycemic effect.
Safety and tolerability
Unlike older appetite suppressants, fenfluramine and 
dexfenfluramine, sibutramine does not cause increased 
serotonin release and has not been associated with the 
development of valvular disease.71,72
However, in view of the associated increased sympathetic 
activity, sibutramine can cause slight elevation in heart rate 
and both diastolic and systolic blood pressure and should 
therefore be used cautiously in patients with uncontrolled 
hypertension, arrhythmia, coronary heart disease or conges-
tive heart failure. It should be avoided as well in patients 
receiving other sympathomimetic drugs, monoamine oxidase 
inhibitors or serotonin uptake inhibitors.
Studies have shown that patients with well controlled 
hypertension on ACE inhibitors or beta blockers with or 
without thiazides appear to achieve significant weight loss 
with sibutramine with no compromise of blood pressure 
control.64,67
The most common side-effects of Sibutramine are usually 
related to sympathomimetic properties, such as dry mouth, 
anorexia, constipation, headaches and insomnia.
Availabiltiy, dosage and administration
Sibutramine is marketed in the US under the brand name 
of Meridia® and in Europe under the name of Reductil®. 
Although below the maximally efficacious dosage, sibutra-
mine is approved at the dosage of 10 or 15 mg daily as 
increased cardiovascular side-effects are reported with higher 
doses. The recommended starting dose is at 10 mg daily and 
can be titrated after 4 weeks of therapy according to patient’s 
response and tolerability. Blood pressure and high rate should 
be monitored during dose titration. Non-responders can be 
identified in the first few weeks of the treatment and unneces-
sary prolonged treatment can be avoided in these patients.
Combination of sibutramine and orlistat
As sibutramine and orlistat act through different mechanisms, 
the combination of the two medications was thought to give 
potential additive benefits in obesity. However several stud-
ies failed to show superiority of the combination on the use 
of sibutramine alone. In one study, 34 obese women who 
had lost an average of 11.6% of initial body weight during 
the prior year of treatment with sibutramine and lifestyle 
modification were randomly assigned to sibutramine plus 
orlistat or sibutramine plus placebo. At 16 weeks, mean 
body weight did not change significantly in either treatment 
arm suggesting no additive effect of the combination of 
orlistat with sibutramine.73 In another 12-week, randomized, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 104
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open-labeled trial, 86 obese subjects were randomly treated 
with sibutramine, orlistat, combination of the two drugs or 
diet alone. Sibutramine and the combination therapy were 
equally effective in reducing BMI, and were both significantly 
more effective than orlistat therapy alone.74 Similar findings 
were reported by other investigators as well.74–76
rimonabant (Acomplia®)
Rimonabant is a selective cannaboid receptor 1 (CBR1) 
antagonist that was previously approved by the European 
Medicinal Evaluation Agency (EMEA), but not by the FDA, 
for long-term treatment of obesity in adjunction with diet 
and exercise.
CB1 are distributed in the brain and adipose tissue; 
when activated by endogenous ligands (anandamide and   
2-arachidonyl glycerol), CB1 receptors stimulate fat and 
sweet food intake. In animals, administration of CBR1 
agonists induce hyperphagia whereas CB1R antagonists 
prevent compensatory overeating during forced starvation 
in rats. High fat diet failed to induce obesity in mice lacking 
CB1R because of a spontaneously reduced caloric intake.77 In 
addition to their role in appetite regulation, CB1R antagonists 
might increase energy expenditure in animal models.
Therefore CB1R blockade has emerged over the past 
decade as a new therapeutic option in obesity and cardio-
vascular risk management.
Three multicenter one-year trials and one two-years trial 
were included in the phase III assessment of Rimonabant 
for treatment of obesity: the Rimonabant in Obesity 
(RIO) – Europe study (N = 1507 obese or overweight 
subjects),78 the RIO-Lipids study (N = 1036 overweight or 
obese patients with dyslipidemia),79 the RIO-Diabetes study   
(N = 1047 overweight or obese patients with uncontrolled 
type 2 diabetes)80 and the RIO-North America (3045 obese 
or overweight adult).81 Rimonabant was consistently associ-
ated with an average additional weight reduction of 4.9 kg 
(dose of 20 mg) and 1.3 kg (dose of 5 mg) compared to 
placebo.82 In addition, rimonabant exhibited consistently 
across these trails several favorable metabolic effects such 
as improvements in waist circumference, HDL-cholesterol, 
triglycerides, insulin resistance, and prevalence of the 
metabolic syndrome.78–83 The metabolic effects were mostly 
observed with the dosage of 20 mg. A potential effect on 
atherosclerosis was also studied.84
According to a systematic review by Curioni, rimonabant 
20 mg caused significantly more adverse effects both of 
general and serious nature, especially of nervous system, 
psychiatric or gastro-intestinal origin.82 Despite similar high 
drop-out rates in rimonabant and placebo groups (36%–49% 
at 1 year), side-effects including mood changes, nausea, vom-
iting, diarrhea, headaches and anxiety were more frequent in 
the rimonabant 20 mg group.
Rimonabant use was associated with increased neuro-
logic and psychiatric adverse effects including seizures, 
depression, anxiety, aggressiveness and suicidal thoughts 
despite depressive mood being an exclusion criteria for the 
clinical trials.85 In 2007, increased suicidal risk raised special 
concern in the FDA panel who advised against the approval 
of the medication in the US. More recently, the European 
Regulatory authorities have removed marketing approval 
for rimonabant because of postmarketing associated serious 
psychiatric side-effects including reported deaths of suicide. 
The manufacturers of the drug subsequently terminated 
clinical trials with rimonabant.




Decades prior to sibutramine, noradrenergic drugs have 
been approved for short-term therapy of obesity and include: 
phentermine (FDA approved in 1959), diethylpropion, 
benzphetamine and phendimetrazine. These medica-
tions stimulate the release of norepinephrine or inhibit its 
reuptake into nerve terminals and act centrally as appetite 
suppressants.
Phenylpropanolamine has been withdrawn from the 
market because of increased risk of hemorrhagic stroke in 
women.86
Other serotonergic agents (fenfluramine and dexfen-
fluramine) were also withdrawn from the US market in 
1997 because of association with valvular heart disease 
and pulmonary hypertension that are believed to be related 
to the nonselective effect of increased serotonin levels on 
cardiac 5HT receptors.87,88
Clinical trials
Most of the data on sympathomimetics come from short-term 
trials. In a meta-analysis, of nine randomized controlled 
studies of phentermine and thirteen clinical trials of diethyl-
propion, phentermine 15 to 30 mg daily and diethylpropion 
75 mg daily were associated with additional 3.6 kg and 3.0 kg 
of weight loss respectively when compared to placebo.89 In 
two 36-week trials, weight loss achieved with phentermine 
was up to 13% of initial body weight, reflecting its high 
efficacy.90Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 105
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Safety and tolerability
Phentermine and diethylpropion are classified by the US 
Drug Enforcement Agency as class IV medications while 
benzphetamine and phendimetrazine are classified as 
class III, suggesting a potential, although low risk of abuse 
with these medications. Although no major side effects were 
reported, these medications could potentially be associated 
with adverse effects related to increased sympathetic drive 
such as insomnia, euphoria, palpitations, dry mouth, and 
increased blood pressure.
Their use is approved for short term, usually up to 
12 weeks and represents the least expensive available obesity 
drugs in the market.
Medications associated with weight loss 
but not approved for obesity treatment
Antidepressants
Selective serotonin reuptake inhibitors (SSris)
Fluoxetine and sertraline are two SSRIs approved for treat-
ment of depression. Their use has been linked with weight 
loss that is thought to be secondary to appetite suppression 
and decreased food intake.
In a meta-analysis of nine studies of fluoxetine used at a 
dose of 60 mg daily (3 times usual dose for depression) as a 
treatment for obesity, the weight reduction with fluoxetine 
ranged from −0.9 kg to −9.1 kg at 6 months and from −14.4 kg 
to +0.3 kg at 12 months compared to placebo. In summary 
at one year the weight regain ablated the previous weight 
loss observed at 6 months, suggesting a limited efficacy of 
fluoxetine to short term therapy.39,91,92
In a study assessing the effect of sertraline in weight 
maintenance in 53 women who lost weight with lifestyle 
changes, there was no significant difference in weight regain 
between sertraline group and placebo group.93
Despite lack of extensive data and demonstrable long-
term efficacy, fluoxetine and sertraline represent a viable 
option in treating obese patients with depression.
Bupropion
Bupropion is approved for treatment of depression and for 
adjunctive therapy for prevention of weight gain in smoking 
cessation. It is a weak serotonin, norepinephrine and dopamine 
reuptake inhibitor with structural similarity to diethylpropion.
Pooled analysis of weight loss from three randomized 
controlled studies showed that bupropion at 400 mg daily was 
associated with a total weight loss of 4.44 kg at 12 months and 
additional 2.77 kg when compared to placebo.39,94 Insomnia and 
dry mouth are commonly reported side-effects. Bupropion is 
contraindicated in patients with seizure disorders. The use of 
bupropion as a weight reducing agent is limited by the lack of 
large trials examining its efficacy in obese patients.
Antiepileptics
Topiramate
A novel antiepileptic agent, topiramate, is approved for 
treatment of seizures and migraine headaches but has been 
observed to be associated with decreased food intake and 
weight loss in multiple seizures studies. The mechanism 
of action on appetite suppression is not clearly understood 
but GABA pathway modulation is a potential mediator of 
weight loss. Several trials have been subsequently conducted 
to assess its efficacy in obesity treatment. In a meta-analysis 
of 6 randomized controlled trials evaluating topiramate as 
a weight reducing agent, topiramate at the dose of 192 mg 
daily was associated with additional 6% of initial body weight 
loss at 6 months when compared to placebo.39 Moreover, 
topiramate seems to play a therapeutic role in binge-eating 
disorders.95,96 Paresthesias, somnolence, attention deficit, 
changes in taste, nonanion gap acidosis and with kidney 
stones are more commonly observed with topriamate treated 
patients. These side-effects have limited the development pro-
gram for topiramate indication for overweight treatment.
Zonisamide
Zonisamide is an antiepileptic drug with serotonergic and 
dopaminergic properties, that has been linked to weight loss 
in epilepsy studies. To examine a potential role in obesity 
treatment, a double-blind, placebo-controlled trial was con-
ducted for 16 weeks, assigning randomly 60 obese subjects 
to receive zonisamide (100 mg up to 600 mg daily) or pla-
cebo, in addition to a hypocaloric diet for both groups.97 At 
16 weeks, zonisamide treatment was associated with greater 
body weight loss when compared to placebo (6% versus 
1%). The participants who entered the single-blind treatment 
extension phase continued to lose weight at 32 weeks.
The most common side-effects associated with the use 
of zonisamide include somnolence, anorexia, dizziness, 
headache, nausea, and irritability.
Antidiabetic medications
Metformin
Metformin is a biguanide used in the treatment of diabetes and 
acts by inhibiting hepatic glucose production and improving 
insulin sensitivity. In diabetic patients, the use of metformin 
was associated with modest weight loss when compared to 
sulfunyloreas and insulin.11,75Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 106
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In the multicenter Diabetes Prevention Trial enrolling 
3234 overweight patients with impaired fasting glucose or 
impaired glucose tolerance test, metformin treatment for 
2.8 years was associated with 2.5% of initial body weight 
loss when compared to placebo, along with a 31% reduction 
in progression to diabetes.16 This effect was more pronounced 
with higher BMI and younger age.
The BIGuanides and Prevention of Risks in Obesity 
(BIGPRO1) study examined the effect of metformin on 
weight and insulin resistance. Among the 324 subjects with 
upper-body obesity, metformin induced a significant weight 
loss (1–2 kg) with significant improvement of metabolic 
syndrome parameters after one year of treatment.98
These results suggest that metformin is a viable therapeu-
tic option in obese or overweight patients at risk for diabetes 
and the metabolic syndrome, and it is the preferred agent in 
treatment of diabetes as well as polyscysitc ovaries syndrome 
in obese subjects.99
The most common side-effect observed with metformin 
is diarrhea and gastro-intestinal disturbances. Metformin use 
should be avoided in patients with renal failure, in view of 
the increased risk of lactic acidosis with biguanides in this 
patient population.
exenatide (Byetta®)
Exenatide is a long acting synthetic glucagon-like polypeptide 1 
(GLP1) receptor agonist that acts through glucose-dependent 
stimulation of insulin secretion, suppression of glucagon 
secretion and slowing of gastric emptying, leading to an 
improvement in glycemic control in diabetic patients and a 
modest weight loss through decreased food intake.100
In a 30-week study of 336 adults with type 2 diabetes on 
metformin, treatment with Exenatide was associated with 
significant dose-dependent weight loss up to 2.8 kg with 
10 µg subcutaneous twice daily compared to placebo.101 
Similar findings were obtained in two other 30-week trials of 
exenatide in patients treated with sulfonylureas and metfor-
min and sulfonylureas alone.102,103 An open-label extension of 
exenatide treatment in two of the trials revealed a significant 
weight loss of 4.4 kg and 5.3 kg at 82 weeks.104,105
Unlike most of the weight loss trials, diet and exercise were 
not component of the therapy in exenatide trials, and all of the 
weight loss described was attributed to the medication.
Nausea is the most common side-effect of exenatide.
Pramlintide (Symlin®)
Pramlintide is a synthetic analog of amylin, which is a peptide 
co-secreted with insulin by pancreatic beta-cells in response 
to food intake. Amylin complements the role of insulin in 
regulating post-meal glucose, suppresses post meal glucagon 
secretion, slows gastric emptying and decreases food intake. 
Pramlintide is approved for treatment of type 1 and type 2 
diabetes with meal time insulin and has been associated with 
decreased food intake and weight loss in clinical trials.106
In a double-blind, placebo-controlled, multicenter study, 
six hundred fifty-one patients with type 1 diabetes were ran-
domized to mealtime injections of placebo or pramlintide, 
in addition to their insulin therapy. At 1 year, addition of 
pramlintide (60 µg with meals) to insulin led to a significant 
reduction in body weight (−0.4 kg weight loss versus +0.8 kg 
weight gain in body weight in the placebo group).107
Pramlintide is particularly interesting in the treatment 
of diabetic patients who experience weight gain associated 
with the use of insulin. Nausea is a common side-effect of 
pramlintide.
experimental drugs
Multiple novel therapeutic agents for obesity are being cur-
rently developed and include either peripherally produced 
peptides or centrally acting neurotransmitters and receptors 
involved in appetite regulation.
Combination therapy
Topiramate/Phentermine (Qnexa®)
Phase III trials with a novel obesity agent combining phenter-
mine and topiramate (Qnexa®) were recently completed and 
revealed promising results. As the two agents induce weight 
reduction via different mechanisms, topiramate through 
GABA and other agonists properties increasing satiety, and 
phentermine through decreasing appetite, an additive effect 
of the combination was expected and was observed in the 
three pivotal phase III trials of the drug. An average of 37 lbs 
(14.7% of body weight) was achieved at 56 weeks of therapy 
with Qnexa in the EQUIP and CONQUER study with 69% 
completion rate, positive tolerability and favorable metabolic 
and safety profile.108
Bupropion Sr/Naltrxone Sr (Contrave®)
Contrave® is another investigational medication for the treat-
ment of obesity completing currently four phase III clinical 
trials. While bupropion is believed to help initiate weight loss, 
the combined naltrexone may sustain the weight reduction by 
blocking the opioid receptors and inhibiting the reinforcing 
and rewarding aspect of addictive substances as observed 
in alcohol abstinence. Two of the four COntrove Obesity 
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revealed that approximately 25%–33% of obese individuals 
lost 10% or more of their body weight and 12% to 16% lost 
at least 15% of body at 56 weeks of therapy with Contrave, 
with demonstrated significant improvements in markers of 
cardiometabolic risk including waist circumference, HDL 
and triglycerides.109
5-HT1Br and 5-HT2Cr selective agonsits
As mentioned earlier, serotoninergic pathway plays a very 
well known role in appetite suppression. The therapeutic 
limitations with earlier potent serotonergic agents such 
as D-fenfluramine were the nonselective effect on 5-HT 
receptors causing different side-effects including valvular 
heart disease. Recently, central 5-HT1BRs and 5-HT2CRs 
receptors have been identified as the 5-HT receptors that 
are specifically involved in body weight and food intake 
control. Pharamceutical research is currently working on 
developing serotonergic agents that specifically target the 
appetite regulation pathway via direct interaction with   
5-HT2cRs and 5-HT1BRs on arcuate POMC and AgRP/
NPY neurons, respectively, with a resulting activation of the 
downstream melanocortin system. Lorcacerin is a new selec-
tive 5-HT2cRs and 5-HT1BRs agonist that is currently in 
phase III trial with three major clinical tials enrolling around 
7800 patients. The results of the first trial, the BLOOM 
(Behavioral modification and Lorcaserin for Overweight and 
Obesity Management) were presented at the 69th Scientific 
Sessions of the American Diabetes Association in June 2009 
with an induced average weight loss of 5.8% of body weight, 
or 12.7 lb, in the lorcaserin group, compared to 2.2%, or 4.7 
lb, for placebo, in addition to favorable metabolic effect and 
absence of associated psychiatric side-effects or valvular 
disease. The BLOSSOM (Behavioral modification and 
LOrcaserin Second Study for Obesity Management) trial 
results were more recently announced revealing an average 
weight loss of 17.0 lb or 7.9% of body weight with lorcacerin 
therapy at one year, compared to 8.7 lb or 3.9% for placebo 
and an achieved average weight loss of 5.9% of body weight 
at 2 years compared to 2.8% for placebo.110
Ghrelin
Ghrelin is a hormone secreted by the gastrointestinal tract 
endocrine cells, particularly in situations of energy insuffi-
ciency or deprivation. It is believed that ghrelin plays a major 
role in feeding control regulation by its potential direct effect 
on central nervous system. Stimulating appetite, lowering 
energy expenditure, shifting diet preference towards food 
rich in fat and increasing the rewarding value of food are all 
potential mechanisms by which ghrelin leads to increased 
body weight and increased adiposity.111,112
In humans, ghrelin levels are generally low in obese 
individuals and increase during weight reduction, potentially 
contributing to weight regain observed typically after initial 
weight loss.113 Interestingly ghrelin levels are suppressed 
after bariatric surgery probably playing a role in the weight 
reduction observed after the procedure.113 On the other hand, 
ghrelin levels have been observed to be very elevated in 
Prader-Willi Syndrome playing very likely a causative role 
in the hyperphagia observed in these patients.114
Multiple animal studies aiming to inactivate normal 
ghrelin signaling pathways have led to significant weight 
reduction with specifically decreased adipose mass along 
with inconsistent effect on energy expenditure and food 
intake. Inhibition of ghrelin is currently being studied and 
developed as a potential weight-reducing agent.115
Leptin
Leptin is one of the peptides secreted by adipose tissue with 
a central effect on hypothalamic appetite center. Historically, 
mice lacking leptin synthesis and activity (ob/ob) are mas-
sively obese and rare cases of humans with leptin deficiency 
are reported to have morbid obesity since childhood and 
responded dramatically to leptin infusion.116 The majority 
of obese subjects have high plasma levels of leptin suggest-
ing a probable leptin resistance that could hypothetically be 
overcome by high dose leptin. In a randomized, double-blind, 
placebo-controlled, multicenter trial, 54 lean and 73 obese 
subjects were randomized to varying doses of recombinant 
methionyl human leptin subcutaneous injection daily or pla-
cebo for 4 weeks with extension of treatment to 20 weeks for 
obese participants.117 Leptin induced significant weight loss 
in a dose-dependent fashion in all subjects at 4 weeks and in 
obese subjects at 24 weeks. Mean weight loss at 24 weeks 
ranged from −0.7 kg for the 0.01 mg/kg dose to −7.1 kg for 
the 0.30 mg/kg dose. In another randomized, double-blind, 
placebo-controlled study of 284 overweight or obese patients, 
leptin injections at 10 mg twice a day did not lead to more 
weight loss at 12 weeks compared to placebo.118
Leptin concentrations were observed to decrease, along 
with thyroid hormone levels, during fasting and energy 
restriction states, suggesting that leptin administration can 
play a role in regulating energy expenditure in these cases. 
To explore this hypothesis, a randomized, double-blind, 
placebo-controlled study was conducted in 22 overweight 
men who were randomized to weekly injection of pegylated 
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low caloric diet for 46 days.119 Treatment with PEG-OB led 
to significant additional weight loss (14.6 kg compared to 
11.8 kg in placebo group) along with a reduction in appetite. 
Another small study suggested that the decreased energy 
expenditure associated with weight loss can be partially 
reversed by leptin treatment, conferring to leptin a potential 
role in preventing weight regain in maintenance phase of 
weight loss.120
In summary, because of this resistance, even high doses 
of leptin have produced only modest success at reducing 
body weight in general obesity. However studies suggest 
that leptin may be effective in enhancing the maintenance 
of weight loss achieved by either lifestyle modifications or 
other drug therapies.
Leptin seems also to improve glycemic control and 
decrease triglycerides level in patients with lipodystrophy 
and leptin deficiency.121
Peptide YY
Peptide YY 3–36 is another appetite-regulating hormone 
under investigation for obesity treatment. It is derived from 
the gastro-intestinal peptide PYY and was shown to decrease 
appetite and food intake in normal subjects by modulating 
appetite circuits in the hypothalamus.122
The effects of PYY infusion on appetite and food intake 
was assessed in a study of 12 obese and 12 lean subjects in 
a double-blind, placebo-controlled, crossover study. PYY 
infusion caused a significant 30% decrease in food intake 
in both lean and obese subjects. Endogenous fasting and 
postprandial levels of PYY were significantly lower in obese 
subjects suggesting that, unlike leptin, obese patients were 
not resistant to the anorectic effects of PYY and that PYY 
deficiency could play a role in the pathophysiology of obe-
sity.123 Intranasal peptide YY (3–36) given before meals in a 
recent study of 133 obese adults did not achieve significant 
higher weight reduction when compared to placebo because 
of a very high discontinuation of the drug secondary to 
associated nausea.124
Oxyntomodulin
Oxyntomodulin is another gastro-intestinal peptide 
secreted in response to meals and playing a role in appetite 
suppression.
In a randomized, double-blind trial, self-injection of 
oxyntomodulin before meals for 4 weeks induced a significant 
weight loss of 2.3 kg in the treatment group compared with 
0.5 kg in the placebo group, along with a significant decrease 
in energy intake in the oxyntomodulin group.125
Melanocortin 4-receptor agonists
The MC4-R hypothalamic signaling pathway plays a major 
role in feeding behavioral control and is regulated by leptin 
responsive endogenous agonists and antagonists. Mutations 
of MC4-R are the most common causes of human monogenic 
obesity and are thought to account for 5% to 10% of com-
mon morbid obesity.126 In animal models, MC4-R absence 
leads to adult onset obesity.127 Moreover, MC4-R deficient 
mice are not able to respond to high fat diets by increasing 
thermogenesis and physical activity, suggesting a potential 
role of the melanocortin system in energy homeostasis.128
Numerous MC4-R agonists are being developed as 
potential targets for obesity therapy.129–131
Other experimental drugs
Several other medications are at different stages of inves-
tigation for their ability to induce weight loss and include: 
tesofensine (sympathomimietic), SIRT 1, peptide analog of 
growth hormone fragnment hGH 177–191, somatostatin, 
Axokine, Neuropeptide Y Receptor antagonists, pancreatic 
lipase inhibitor (cetilistat), cholecystokinin, beta3 adrenergic 
receptors agonists, and combination of anti-obesity drugs, 
in addition to multiple experimental drugs in early phase of 
development.132
Clinical viewpoints
When prescribing medications for obesity, physicians 
should be familiar with certain aspects of weight reducing 
pharmacologic agents:
–  The pharmacologic agents should always be given in 
conjunction with diet and exercise as therapeutic effect 
observed in the trials applied to patients who were following 
lifestyle changes and having close medical follow-ups. The 
efficacy of medication alone would probably be reduced 
by at least 50% if not combined to behavioral changes.59
–  The efficacy of the medication can be measured by the 
amount of weight loss and the improvement of comorbidi-
ties. Responders will usually lose at least 2 kg during the first 
month of therapy and 5% of body weight at 3 to 6 months 
of therapy. Patients who do not respond within 4 weeks of 
therapy are unlikely to benefit from the medication and 
should not be exposed to unnecessary prolonged therapy.
–  The efficacy of weight reducing agents is limited by a 
maximal weight loss that usually peaks at 6 to 12 months 
and generally does not exceed 10% of body weight. 
However, as mentioned earlier, such a moderate effect 
would lead to favorable metabolic outcomes as observed 
in most of the clinical trials.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 109
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–  Patients will typically start regain weight during the second 
year of therapy, though to a lesser degree than patients on 
placebo, fact that is believed to be related to decreased 
body energy expenditure after weight loss.
–  Long-term compliance with lifestyle changes and phar-
macotherapy has been suboptimal as reflected by the 
consistent high drop-out percentage in both placebo and 
intervention arms of the trials.
–  The weight reducing agents work when taken and their 
beneficial effect subsides after discontinuation of therapy. 
The longest trial duration was 2 years for sibutramine and 
4 years for orlistat. It is therefore unclear how to manage 
patients after 2 or 4 years of therapy.
–  It is of extreme importance to discuss the expected effects 
and side-effects of pharmacotherapy with obese patients 
to avoid unnecessary frustrations and discontinuation 
of therapy. Patients treated with weight reducing agents 
should be followed regularly to encourage compliance, 
assess efficacy and monitor side effects of therapy.
Conclusion
Despite the rising tide of the obesity epidemic worldwide with 
its enormous impact on morbidity and mortality together with 
the massive healthcare cost, only a few medical therapeutic 
options are currently available for long-term weight loss, 
that have been shown to be safe and effective. These agents 
include orlistat and sibutramine. With these agents, however, 
weight loss is modest and long-term beneficial effects on 
cardiovascular end-points remain to be established.
The gigantic nature of this obesity epidemic has led to 
deeper understanding, over the past decades, of appetite 
regulation and weight control pathways, opening the horizons 
to many potential drugs for assisted weight loss. Obesity is 
currently one of the most active research fields with the hope 
that novel therapeutic agents can help curving the growing 
pandemic of obesity and its associated comorbidities.
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